Dyschromatosis universalis hereditaria (DUH) is a rare genodermatosis where the affected manifests mottled pigmentation with intermingled hyper-and hypo-pigmented macules. On most occasions, the lesions begin on limbs and then extend to trunk. Most of the cases reported in literature are from Japan. It is rarer in Indians. In this report, we describe a 12-year-old male child with DUH, who showed response to narrow-band ultraviolet-B therapy.
Introduction
Described by Ichikawa and Higara, dyschromatosis universalis hereditaria (DUH) remains a rare genodermatosis. [1] Most cases reported are from Japan though there are occasional reports from other parts of the world including India. We report a child with the disease who showed moderate response to narrow-band ultraviolet-B (NBUVB).
Case Report
A 12-year-old male child of nonconsanguineous marriage presented with interspersed depigmented and hyperpigmented macules involving the trunk [ Figure 1a ], proximal part of upper arms, buttocks, upper thighs, and dorsal aspect of middle phalanges of fingers with scattered lesions on the face. Photosensitivity was absent. The lesions started appearing on the trunk at the age of 1 year and then progressively increased. His growth and development were normal. There was no history of seizures or reduced sweating. His scholastic performance was average. None of his family members were similarly affected. There was no history of exposure to any chemicals.
He showed no xerosis, atrophy, or telangiectasia. Palms and soles were spared. Hair, teeth, and nails were normal. Mucosae were uninvolved except for depigmentation noted on both upper and lower lips.
Laboratory parameters including serology for human immunodeficiency virus infection were negative.
Representative lesions from both the depigmented and hyperpigmented macules were biopsied. Reduced and increased basement membrane pigmentations were noted in the depigmented [ Figure 2 ] and hyperpigmented areas [ Figure 3] , respectively, suggesting a diagnosis of DUH. [2] The absence of photosensitivity, xerosis, atrophy, and telangiectasia observed in our case was not in favour of xeroderma pigmentosum. The child and parents were counseled regarding the benign disease course and the unsatisfactory response to treatment modalities. He was offered NBUVB thrice a week and showed moderate response after 3 months [ Figure 1b ].
Discussion
DUH is considered as the generalized form of a disease spectrum including dyschromatosis universalis hereditaria, dyschromatosis symmetrica hereditaria, or acropigmentation of Dohi (confined to extremities) and a segmental form called unilateral dermatomal pigmentary dermatosis, where the affected presents with intermingled hypo-and hyper-pigmented macules. [2] DUH shows autosomal dominant or recessive pattern of inheritance.
[2] Sporadic cases like ours have been reported occasionally. [3, 4] Often, it begins in early childhood and mostly involves trunk and extremities. Face is affected in 50% of cases. Involvement of palms, soles, hair, and nails is recorded occasionally. [2] Most reports document lesions beginning on extremities and extending to trunk, but some patients like ours had lesions manifesting on the trunk and then extending to limbs. Interestingly, in the two other cases, where lesions started on the trunk and extended to involve limbs also, no family history could be elicited as in our patient. [3, 4] A localized form has been described by Dhar and Malakar. [5] DUH is considered as a disorder of melanosome synthesis rate or melanocyte activity, rather than a disorder of melanocyte numbers. [6] The moderate response observed following NBUVB by us and by Yadalla et al. points to a role for phototherapy. [2] We report this case to highlight the need to explore the option of NBUVB in similar instances.
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